Tag Archives: Biotechnology Industry

Harder, Better, Faster, Stronger: Takeaways from Partnering For Cures 2012

Drug Manufacturing

The chorus to Kanye West’s 2007 chart-topper Stronger can teach us volumes about speeding drug development. Harder:  Drug development is challenging.  It takes over 10 years and more than $1 billon to bring a therapy through the product pipeline, from the research lab to clinical trials to FDA approval to prescription to patients suffering from the disease. The FDA approved over 30 innovative drugs last year, including more than 10 new treatments for cancer—a good Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Small Companies, Big Returns

The broader biotech indices are up more than 30 percent this year and have reached levels not seen since the peak of March 2000. Larger biotechs account for much of the index returns, as we have described previously, and have helped the sector outperform the S&P 500 by two fold. But how have smaller biotech companies been performing? As of Nov 30, 27 companies that started the year under $1 billion in market capitalization have Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Are Politics Killing the U.S. Animal Biotech Industry?

salmon

A number of national newspapers ran an in-depth Associated Press article this week on the continuing saga of the AquAdvantage salmon and the challenge of its developer, Massachusetts-based AquaBounty Technologies, to stay afloat. The fish, genetically engineered to reach market weight in half the time of a conventional salmon, is a sustainable answer to the world’s demand for high-quality seafood protein, but its application for approval with the U.S. Food and Drug Administration (FDA) remains Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Big Ventures

It is rare to see triple digit millions in private financing rounds, but it does happen once or twice a year on average. In the headlines last week, was the largest triple digit VC round in years – the $160M in venture capital funding for Intarcia. With the simultaneous debt financing of $50M, the total funding round was $210M. Behind the deal were existing investors New Enterprise Associates, New Leaf Venture Partners and Venrock, plus Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

The Good, the Bad, and the Ugly for Biotech IPOs

2012-11-12-Technology-vs-HC-IPOs-btn

The troubles in the biotech IPO market are complicated to explain to industry outsiders. They read about new biotechs debuting on the public market, but also hear bankers, VCs, and CEOs complaining about how the IPO window never really opened after 2008. The reality is that we are seeing positive developments and negative trends simultaneously. On the bright side, the cumulative number of IPOs is holding up. The recent pace of biotech IPOs mimics what Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,